Erkki Ruoslahti

This study evaluates the neuroprotective effects of the tetrapeptide CAQK in TBI models, showing reduced injury size, inflammation, and functional deficits.

This paper identifies a cyclic peptide, CES, that targets glioblastoma by binding to aberrantly exposed SNAP25, showing its potential as a drug delivery tool and molecular marker.